Toggle light / dark theme

Graphene has already proven its importance to brain implants as well as other Synbio technology.


Brain cell culture. Left: Normal astrocyte brain cell; Right: cancerous Glioblastoma Multiforme (GBM) version, imaged by Raman spectrography. (credit: B. Keisham et al./ACS Appl. Mater. Interfaces)

By interfacing brain cells with graphene, University of Illinois at Chicago researchers have differentiated a single hyperactive Glioblastoma Multiforme cancerous astrocyte cell from a normal cell in the lab — pointing the way to developing a simple, noninvasive tool for early cancer diagnosis.

In the study, reported in the journal ACS Applied Materials & Interfaces, the researchers looked at lab-cultured human brain astrocyte cells taken from a mouse model. They compared normal astrocytes to their cancerous counterpart, highly malignant brain tumor glioblastoma multiforme.

Rejuvenating the immune system offers hope for Alzheimer’s patients and removal of plaques.


Alzheimer′s disease (AD) is characterized by deposition of amyloid plaques, neurofibrillary tangles, and neuroinflammation. In order to study microglial contribution to amyloid plaque phagocytosis, we developed a novel ex vivo model by co‐culturing organotypic brain slices from up to 20‐month‐old, amyloid‐bearing AD mouse model (APPPS1) and young, neonatal wild‐type (WT) mice. Surprisingly, co‐culturing resulted in proliferation, recruitment, and clustering of old microglial cells around amyloid plaques and clearance of the plaque halo. Depletion of either old or young microglial cells prevented amyloid plaque clearance, indicating a synergistic effect of both populations. Exposing old microglial cells to conditioned media of young microglia or addition of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) was sufficient to induce microglial proliferation and reduce amyloid plaque size. Our data suggest that microglial dysfunction in AD may be reversible and their phagocytic ability can be modulated to limit amyloid accumulation. This novel ex vivo model provides a valuable system for identification, screening, and testing of compounds aimed to therapeutically reinforce microglial phagocytosis.

Read more

Non-profit research ultimately benefits for-profit companies and is an essential part of the development chain of any therapy.


Companies like Unity Biotech have taken non-profit research and are developing it for-profit, this is the only way that therapies will make it to market and pay for the huge costs involved in development. You may have concerns that our current crowdfunding project is with a for-profit company so here is CellAge to answer this question.

Their campaign can be found at Lifespan.io here:

The body is under constant invasion by microbes so rejuvenation of the immune system and reduction of imflammation is a big priority for rejuvenation biotechnology.


Recent publications have proposed that aging should be classified as a disease (Bulterijs et al., 2015; Zhavoronkov and Bhullar, 2015; Zhavoronkov and Moskalev, 2016). The goal of this manuscript is not to dispute these claims, but rather to suggest that when classifying aging as a disease, it is important to include the contribution of microbes.

As recently as ~115 years ago, more than half of all deaths were caused by infectious diseases, including pneumonia, influenza, tuberculosis, gastrointestinal infections, and diphtheria (Jones et al., 2012). Since then, the establishment of public health departments that focused on improved sanitation and hygiene, and the introduction of antibiotics and vaccines allowed for a dramatic decrease in infectious disease-related mortality (Report, 1999). In 2010, the death rate for infectious diseases was reduced to 3% (Jones et al., 2012). Simultaneously, as infectious disease-related mortality rates have decreased, global lifespan has increased from ~30 to ~70 years (Riley, 2005).

Because death rates due to infectious diseases have been reduced to very low levels, we’ve forgotten about the adverse effects of microbes on our existence. The fact is, we live in a microbial world. Although there are currently ~7 billion people, in contrast, the total number of prokaryotes and viruses have been estimated at 1030 and 1031, respectively (Whitman et al., 1998; Duerkop et al., 2014). Even without including other microbes (e.g., fungi, protozoa), humans are outnumbered by more than 1021 to 1! All of these microorganisms aren’t detrimental to human health, but more than 1400 microbial species have been shown to be pathogenic (Taylor et al., 2001).

Leaves are kind of like nature’s power plants, converting incoming sunlight into energy for the plant to thrive on. Inspired by the real thing, scientists have previously created artificial leaves that function in much the same way as their natural counterparts to produce electricity and even liquid fuels. Now a team at Eindhoven University of Technology (TU/e) is using a similar system to produce chemicals, which could one day lead to solar-powered “mini-factories” that can produce drugs, pesticides and other chemicals almost anywhere.

To mimic the light-capturing molecules in leaves, the researchers turned to luminescent solar concentrators (LSCs), materials seen in solar-harvesting window technology and used to catch and amplify laser beams carrying data in Facebook’s drone-mounted internet projec t. These LSCs absorb incoming light, convert it to specific wavelengths and then guide the photons to the edges of the device.

The TU/e team’s take on the idea was to create a leaf-shaped device, made from a silicon rubber LSC, with a thin channel running through it like the veins in a leaf. As chemicals are pumped through the channel, the LSC material directs sunlight towards it, and the high intensity of the sunlight can trigger a chemical reaction with the liquid in the channel. Essentially, one substance enters, and by the time it comes out the other end, the device will have converted it into a different chemical, which may be useful as a drug, fuel or other agent.

Read more

The bionic pancreas system developed by Boston University (BU) investigators proved better than either conventional or sensor-augmented insulin pump therapy at managing blood sugar levels in patients with type 1 diabetes living at home, with no restrictions, over 11 days. The report of a clinical trial led by a Massachusetts General Hospital (MGH) physician is receiving advance online publication in The Lancet.

“For study participants living at home without limitations on their activity and diet, the bionic pancreas successfully reduced average blood glucose, while at the same time decreasing the risk of hypoglycemia,” says Steven Russell, MD, PhD, of the MGH Diabetes Unit. “This system requires no information other than the patient’s body weight to start, so it will require much less time and effort by health care providers to initiate treatment. And since no carbohydrate counting is required, it significantly reduces the burden on patients associated with diabetes management.”

Developed by Edward Damiano, PhD, and Firas El-Khatib, PhD, of the BU Department of Biomedical Engineering, the bionic pancreas controls patients’ blood sugar with both insulin and glucagon, a hormone that increases glucose levels. After a 2010 clinical trial confirmed that the original version of the device could maintain near-normal blood sugar levels for more than 24 hours in adult patients, two follow-up trials — reported in a 2014 New England Journal of Medicine paper — showed that an updated version of the system successfully controlled blood sugar levels in adults and adolescents for five days. Another follow-up trial published in The Lancet Diabetes and Endocrinology in 2016 showed it could do the same for children as young as 6 years of age.

Read more

Nice.


Scientists have enlisted the exotic properties of graphene, a one-atom-thick layer of carbon, to function like the film of an incredibly sensitive camera system in visually mapping tiny electric fields in a liquid. Researchers hope the new method will allow more extensive and precise imaging of the electrical signaling networks in our hearts and brains.

The ability to visually depict the strength and motion of very faint electrical fields could also aid in the development of so-called lab-on-a-chip devices that use very small quantities of fluids on a microchip-like platform to diagnose disease or aid in drug development, for example, or that automate a range of other biological and chemical analyses. The setup could potentially be adapted for sensing or trapping specific chemicals, too, and for studies of light-based electronics (a field known as optoelectronics).

“This was a completely new, innovative idea that graphene could be used as a material to sense electrical fields in a liquid,” said Jason Horng, a co-lead author of a study published Dec. 16 in Nature Communications that details the first demonstration of this graphene-based imaging system.

Herbs treating Tuberculosis.


A centuries-old herbal medicine, discovered by Chinese scientists and used to effectively treat malaria, may help treat tuberculosis and slow the evolution of drug resistance.

A new study shows the ancient remedy artemisinin stopped the ability of TB-causing bacteria, known as Mycobacterium tuberculosis, to become dormant. This stage of the disease often makes the use of antibiotics ineffective.

The study is published in the journal Nature Chemical Biology.